Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.

Zhang X, Liu R, Hu Y, Ye J, Yang M, Xu J, Yang H, Yang X, Xu Z, Dai H, Xu H

DOI: 10.2147/rmhp.s617441
Published: 2026
Container: Risk management and healthcare policy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2147/rmhp.s617441,
  title = {Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.},
  author = {Zhang X and Liu R and Hu Y and Ye J and Yang M and Xu J and Yang H and Yang X and Xu Z and Dai H and Xu H},
  year = {2026},
  journal = {Risk management and healthcare policy},
  doi = {10.2147/rmhp.s617441},
  url = {https://doi.org/10.2147/rmhp.s617441}
}

RIS

TY  - JOUR
TI  - Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.
AU  - Zhang X
AU  - Liu R
AU  - Hu Y
AU  - Ye J
AU  - Yang M
AU  - Xu J
AU  - Yang H
AU  - Yang X
AU  - Xu Z
AU  - Dai H
AU  - Xu H
PY  - 2026
JO  - Risk management and healthcare policy
DO  - 10.2147/rmhp.s617441
UR  - https://doi.org/10.2147/rmhp.s617441
ER  -

APA

X, Z., R, L., Y, H., J, Y., M, Y., J, X., H, Y., X, Y., Z, X., H, D., & H, X. (2026). Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.. Risk management and healthcare policy. https://doi.org/10.2147/rmhp.s617441

Source records

pubmed · retrieved 2026-09-26T21:54:28.030Z